What's a fair offer from Pfizer?, page-37

Not sure I see any similarity here. Fitbit were a business with something north of $1.5 billion in annual revenue before they were acquired by Google. They had a product that was already monetised (if I’m missing your point please set me straight).

As to how you ‘value’ this FDA approval, that depends how many extra devices they’re able to sell based on this new feature, and how that translates into ARR, and what forward growth/earnings projections they can bake into it?